Celyad Oncology (CYAD) Set to Announce Earnings on Friday

Celyad Oncology (NASDAQ:CYADGet Rating) is scheduled to be releasing its earnings data before the market opens on Friday, August 5th.

Celyad Oncology Stock Down 15.2 %

Shares of CYAD opened at $1.84 on Thursday. Celyad Oncology has a twelve month low of $1.51 and a twelve month high of $5.32. The company has a current ratio of 2.58, a quick ratio of 2.58 and a debt-to-equity ratio of 0.04. The business’s 50-day moving average price is $1.86 and its 200-day moving average price is $2.31.

About Celyad Oncology

(Get Rating)

Celyad Oncology SA, a clinical-stage biopharmaceutical company, focuses on the discovery and development of chimeric antigen receptor T (CAR-T) cell therapies for the treatment of cancer. Its lead product candidates include CYAD-101, an allogeneic CAR-T candidate that is in Phase 1b clinical trial for the treatment of metastatic colorectal cancer; CYAD-211, a short hairpin RNA (shRNA)-based allogeneic CAR-T candidate, which is in Phase 1 clinical trial to treat relapsed / refractory multiple myeloma; and CYAD-02, an autologous CAR-T candidate that is in Phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes.

Read More

Receive News & Ratings for Celyad Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celyad Oncology and related companies with MarketBeat.com's FREE daily email newsletter.